In compliance with current regulations, let us know which audience you belong to:
Download free resources to get things started with our technologies.
Don't find what you were looking for?
We believe Intense Pulsed Light (IPL) is great, but it isn't effective enough. Following years of research, Espansione Group has developed an innovative photobiomodulation technology, Light Modulation® LLLT for the treatment of the ocular surface (anterior segment) and beyond onto the retina with dry AMD applications (currently under LightWave II clinical trial).
Introducing Light Modulation® Low-level Light Therapy—a radically different technology and approach. By pairing it with Optimal Power Energy® IPL, Espansione Group’s very own, enhanced IPL technology, Espansione Group was able to resolve common IPL limitations, setting a new standard in ocular surface treatment.
“Combined OPE® IPL and LM® LLLT therapies in a single treatment produced significant improvements in tear breakup time and MGD grading scores, with an associated improvement in the patient’s subjective OSDI score.”
STONECIPHER, KARL, ET AL. COMBINED LOW LEVEL LIGHT THERAPY AND INTENSE PULSED LIGHT THERAPY FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION. CLINICAL OPHTHALMOLOGY (AUCKLAND, NZ), 2019, 13: 993.
We’re pioneering what’s next in retinal care, starting with dry AMD management through two large-scale global multi-centric research studies.
Learn more on our research efforts to prevent and manage dry AMD, LightWave I and LightWave II, and dive deeper on Light Modulation® LLLT.
Throughout the years, valued members of the scientific community have contributed to the resonance of Espansione technologies such as Light Modulation® LLLT and Optimal Power Energy® IPL by publishing a vast array of research and scientific, peer-reviewed papers.
To have a practitioner-to-practitioner conversation, learn about the forefront of scientific research, or make sure you provide the best care to your patients, get in touch with our Medical Affairs team.
The latest, from us. Publications,
press releases, and more.